'Excepting the US, which has an implant in someway close to the CGCRI product, in other countries the available ones are made of materials like metal, glass, polymet etc which are inferior in certain respects,' Banerjee said.

IFGL has targeted selling 5,000 implants in 2009-10, 25,000 in 2010-11 and 125,000 in 2011-12, Agarwal said.

With each implant costing Rs.3,500, the company expects to generate business worth Rs. 437.5 million by 2011-12.

'We are targeting the South Asian countries like Bangladesh and Sri Lanka, besides Europe's Denmark and the South American nation of Ecuador to reach our target, besides tapping all parts of India,' he said.

'In 2011-12, we will endeavour to enter markets like USA, where approval of Food and Drug Administration is required,' Agarwal added.